241 related articles for article (PubMed ID: 27890855)
1. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
Cazzamalli S; Corso AD; Neri D
J Control Release; 2017 Jan; 246():39-45. PubMed ID: 27890855
[TBL] [Abstract][Full Text] [Related]
2. Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma.
Cazzamalli S; Dal Corso A; Neri D
Mol Cancer Ther; 2016 Dec; 15(12):2926-2935. PubMed ID: 27609641
[TBL] [Abstract][Full Text] [Related]
3. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
Krall N; Pretto F; Mattarella M; Müller C; Neri D
J Nucl Med; 2016 Jun; 57(6):943-9. PubMed ID: 26912427
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Cazzamalli S; Ziffels B; Widmayer F; Murer P; Pellegrini G; Pretto F; Wulhfard S; Neri D
Clin Cancer Res; 2018 Aug; 24(15):3656-3667. PubMed ID: 29691298
[No Abstract] [Full Text] [Related]
5. Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
Cazzamalli S; Dal Corso A; Widmayer F; Neri D
J Am Chem Soc; 2018 Feb; 140(5):1617-1621. PubMed ID: 29342352
[TBL] [Abstract][Full Text] [Related]
6. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS
Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036
[TBL] [Abstract][Full Text] [Related]
7. Tumor Targeting with Small Molecule-Drug Conjugates (SMDCs) - Can They be Better than ADCs?
Altmann KH
Chimia (Aarau); 2018 Mar; 72(3):154-155. PubMed ID: 29631670
[No Abstract] [Full Text] [Related]
8. Acetazolamide-based [
More KN; Lee JY; Kim DY; Cho NC; Pyo A; Yun M; Kim HS; Kim H; Ko K; Park JH; Chang DJ
Bioorg Med Chem Lett; 2018 Mar; 28(5):915-921. PubMed ID: 29422388
[TBL] [Abstract][Full Text] [Related]
9. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.
Gébleux R; Stringhini M; Casanova R; Soltermann A; Neri D
Int J Cancer; 2017 Apr; 140(7):1670-1679. PubMed ID: 27943268
[TBL] [Abstract][Full Text] [Related]
10. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
Alsaab HO; Sau S; Alzhrani RM; Cheriyan VT; Polin LA; Vaishampayan U; Rishi AK; Iyer AK
Biomaterials; 2018 Nov; 183():280-294. PubMed ID: 30179778
[TBL] [Abstract][Full Text] [Related]
11. Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.
Dal Corso A; Cazzamalli S; Gébleux R; Mattarella M; Neri D
Bioconjug Chem; 2017 Jul; 28(7):1826-1833. PubMed ID: 28662334
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Amiri A; Le PU; Moquin A; Machkalyan G; Petrecca K; Gillard JW; Yoganathan N; Maysinger D
Eur J Pharm Biopharm; 2016 Dec; 109():81-92. PubMed ID: 27702686
[TBL] [Abstract][Full Text] [Related]
13. PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers.
Savoy EA; Olatunji FP; Fulton MD; Kesic BN; Herman JW; Romero O; Maniatopoulos M; Berkman CE
Bioorg Med Chem Lett; 2024 Jan; 98():129573. PubMed ID: 38052377
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice.
Ziffels B; Stringhini M; Probst P; Fugmann T; Sturm T; Neri D
Mol Cancer Ther; 2019 Sep; 18(9):1544-1554. PubMed ID: 31213507
[TBL] [Abstract][Full Text] [Related]
15. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
16. Targeting carbonic anhydrase IX with small organic ligands.
Wichert M; Krall N
Curr Opin Chem Biol; 2015 Jun; 26():48-54. PubMed ID: 25721398
[TBL] [Abstract][Full Text] [Related]
17. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
[TBL] [Abstract][Full Text] [Related]
18. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker.
Oflazoglu E; Stone IJ; Gordon K; Wood CG; Repasky EA; Grewal IS; Law CL; Gerber HP
Clin Cancer Res; 2008 Oct; 14(19):6171-80. PubMed ID: 18809969
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of multivalent drug delivery system with CA IX inhibitors as ligands.
Ding M; Zhu Q; Lu W; Zhu S
Bioorg Med Chem; 2023 Oct; 93():117456. PubMed ID: 37678058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
